The University of Chicago Header Logo

Connection

Thomas F. Gajewski to Cytotoxicity, Immunologic

This is a "connection" page, showing publications Thomas F. Gajewski has written about Cytotoxicity, Immunologic.
Connection Strength

1.575
  1. Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8+ T cells. Eur J Immunol. 2008 Sep; 38(9):2438-50.
    View in: PubMed
    Score: 0.306
  2. Cutting edge: cytotoxic granule polarization and cytolysis can occur without central supramolecular activation cluster formation in CD8+ effector T cells. J Immunol. 2005 Nov 01; 175(9):5581-5.
    View in: PubMed
    Score: 0.251
  3. Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-?-signaling mutant cancer cells. Nat Commun. 2020 01 30; 11(1):602.
    View in: PubMed
    Score: 0.169
  4. Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1. J Immunol. 1999 Oct 15; 163(8):4109-13.
    View in: PubMed
    Score: 0.165
  5. Innate immune recognition of cancer. Annu Rev Immunol. 2015; 33:445-74.
    View in: PubMed
    Score: 0.119
  6. Conditional deletion of PTEN in peripheral T cells augments TCR-mediated activation but does not abrogate CD28 dependency or prevent anergy induction. J Immunol. 2013 Aug 15; 191(4):1677-85.
    View in: PubMed
    Score: 0.107
  7. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood. 2009 Aug 20; 114(8):1545-52.
    View in: PubMed
    Score: 0.080
  8. Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol. 2007 Aug 01; 179(3):1960-8.
    View in: PubMed
    Score: 0.071
  9. The p815 mastocytoma tumor model. Curr Protoc Immunol. 2001 May; Chapter 20:Unit 20.4.
    View in: PubMed
    Score: 0.046
  10. Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice. J Immunol. 2000 Dec 01; 165(11):6024-8.
    View in: PubMed
    Score: 0.045
  11. Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG(-/-) mice. J Immunol. 1997 Nov 15; 159(10):4665-75.
    View in: PubMed
    Score: 0.036
  12. Cutting Edge: Engineering Active IKKß in T Cells Drives Tumor Rejection. J Immunol. 2016 Apr 01; 196(7):2933-8.
    View in: PubMed
    Score: 0.032
  13. B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro. J Immunol. 1996 Jan 15; 156(2):465-72.
    View in: PubMed
    Score: 0.032
  14. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol. 1994 Dec; 24(12):3038-43.
    View in: PubMed
    Score: 0.029
  15. Differential regulation of murine T lymphocyte subsets. Annu Rev Immunol. 1993; 11:29-48.
    View in: PubMed
    Score: 0.026
  16. Production of TH1 and TH2 cell lines and clones. Curr Protoc Immunol. 2006 May; Chapter 3:3.13.1-3.13.15.
    View in: PubMed
    Score: 0.016
  17. B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J Exp Med. 2003 Jun 16; 197(12):1721-30.
    View in: PubMed
    Score: 0.013
  18. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity. 2002 Dec; 17(6):737-47.
    View in: PubMed
    Score: 0.013
  19. Antigen-specific blockade of T cells in vivo using dimeric MHC peptide. J Immunol. 2001 Sep 01; 167(5):2555-60.
    View in: PubMed
    Score: 0.012
  20. Phenotypic and functional analysis of murine CD3+,CD4-,CD8- TCR-gamma delta-expressing peripheral T cells. J Immunol. 1989 Jun 01; 142(11):3754-62.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.